1. Home
  2. BTAI vs CARV Comparison

BTAI vs CARV Comparison

Compare BTAI & CARV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTAI
  • CARV
  • Stock Information
  • Founded
  • BTAI 2017
  • CARV 1948
  • Country
  • BTAI United States
  • CARV United States
  • Employees
  • BTAI N/A
  • CARV N/A
  • Industry
  • BTAI Biotechnology: Pharmaceutical Preparations
  • CARV Savings Institutions
  • Sector
  • BTAI Health Care
  • CARV Finance
  • Exchange
  • BTAI Nasdaq
  • CARV Nasdaq
  • Market Cap
  • BTAI 8.3M
  • CARV 9.6M
  • IPO Year
  • BTAI 2018
  • CARV 1994
  • Fundamental
  • Price
  • BTAI $5.48
  • CARV $1.80
  • Analyst Decision
  • BTAI Strong Buy
  • CARV
  • Analyst Count
  • BTAI 4
  • CARV 0
  • Target Price
  • BTAI $40.00
  • CARV N/A
  • AVG Volume (30 Days)
  • BTAI 22.4M
  • CARV 58.4K
  • Earning Date
  • BTAI 08-12-2025
  • CARV 08-13-2025
  • Dividend Yield
  • BTAI N/A
  • CARV N/A
  • EPS Growth
  • BTAI N/A
  • CARV N/A
  • EPS
  • BTAI N/A
  • CARV N/A
  • Revenue
  • BTAI $868,000.00
  • CARV $22,032,000.00
  • Revenue This Year
  • BTAI N/A
  • CARV N/A
  • Revenue Next Year
  • BTAI $328.13
  • CARV N/A
  • P/E Ratio
  • BTAI N/A
  • CARV N/A
  • Revenue Growth
  • BTAI N/A
  • CARV N/A
  • 52 Week Low
  • BTAI $1.17
  • CARV $1.30
  • 52 Week High
  • BTAI $13.36
  • CARV $3.20
  • Technical
  • Relative Strength Index (RSI)
  • BTAI 67.45
  • CARV 44.68
  • Support Level
  • BTAI $1.30
  • CARV $2.25
  • Resistance Level
  • BTAI $8.08
  • CARV $1.89
  • Average True Range (ATR)
  • BTAI 1.23
  • CARV 0.17
  • MACD
  • BTAI 0.33
  • CARV -0.05
  • Stochastic Oscillator
  • BTAI 61.65
  • CARV 17.89

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

About CARV Carver Bancorp Inc.

Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.

Share on Social Networks: